Clinical Research Directory
Browse clinical research sites, groups, and studies.
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Summary
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2025-08-17
Completion Date
2027-04-06
Last Updated
2025-08-21
Healthy Volunteers
No
Conditions
Interventions
JS203 in combination with gemcitabine and oxaliplatin
Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
JS203 in combination with ifosfamide, carboplatin and etoposide
Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
JS203 combined with lenalidomide
lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
Locations (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China